<DOC>
	<DOCNO>NCT00919763</DOCNO>
	<brief_summary>This multi-center , randomize , double-blind , parallel group study . Efficacy Objectives : To evaluate efficacy CD2027 ointment 3 mcg/g apply twice daily 4 week versus vehicle adult subject least moderate atopic dermatitis . Safety objective : To evaluate safety CD2027 ointment 3 mcg/g apply twice daily 4 week versus vehicle 5 % - 20 % involve BSA ( exclude Head/Neck ) adult subject least moderate atopic dermatitis .</brief_summary>
	<brief_title>Efficacy Safety Study CD2027 Ointment 3 Mcg/g Twice Daily Treatment Adults With Least Moderate Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Male female subject , 18 year age old Clinical diagnosis atopic dermatitis accord Hanifin Rajka criterion , least moderate intensity accord Investigator Global Assessment ( IGA great equal 3 ) Body surface affect disease 5 % 20 % total BSA , base Rule Nine 's , exclude Head/Neck . At least one area ( Target Lesion ) : representative subject 's disease state , locate hand , foot genitalia , measure least 10 cmÂ² , present Total Severity Score least 6/15 ( total severity score define sum Erythema , Excoriation , Papulation/Induration , Oozing/Crusting Lichenification ) oozing/crusting severity 1 The subject albuminadjusted calcium upper normal range screen evaluation . The subject history/signs/symptoms suggestive abnormality calcium homeostasis ( hyperparathyroidism , Paget 's disease , adrenal insufficiency , hyperthyroidism ) The subject signs/symptoms urinary stone history urinary stone within past 5 year prior Screening Visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Atopic Dermatitis</keyword>
</DOC>